article Open AccessTop 1% cited

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

Leukemia · 2015 · Vol. 29(8) · pp. 1637–1647

Saad S. Kenderian✉(University of Pennsylvania)Marco Ruella(University of Pennsylvania)Olga Shestova(University of Pennsylvania)Michael Klichinsky(University of Pennsylvania)Vania Aikawa(University of Pennsylvania)Jennifer J.D. Morrissette(University of Pennsylvania)John Scholler(University of Pennsylvania)Dawei Song(University of Pennsylvania)David Porter(University of Pennsylvania)Martin Carroll(University of Pennsylvania)Carl H. June(University of Pennsylvania)Saar Gill(University of Pennsylvania)

View via DOI Publisher page

CAR-T cell therapy research Virus-based gene therapy research RNA Interference and Gene DeliveryCD33Myeloid leukemiaGemtuzumab ozogamicinLeukemiaChimeric antigen receptorMyeloidHaematopoiesisCancer researchImmunologyMedicine

MeSH terms

AnimalsBlast CrisisFemaleFlow CytometryHumansImmunoenzyme TechniquesMice, TransgenicMyelodysplastic SyndromesReceptors, Antigen, T-CellRNA, MessengerTumor Cells, CulturedBlotting, WesternLeukemia, Myeloid, AcuteMice, SCIDMice, Inbred NOD

Citations

425

FWCI

19.69

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel